Meaningful outcome data are tumour-specific, stage-specific and reported from experienced centres. This page does not quote cure rates or complication percentages, because those numbers without full context can mislead.
Peer-reviewed journal articles, conference abstracts that led to full papers, and prospectively collected institutional series each have strengths and limits. Regulatory databases list device indications that differ by country.
Your team will schedule imaging and blood tests according to the tumour type treated. The interval and modality (MRI, CT, ultrasound, PSA trajectory, etc.) are not the same for prostate, liver, pancreas or kidney.
You can ask for a second opinion on imaging, diagnosis and treatment options before you decide.